Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

Similar Items

• Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
  od: Leone, Gianmarco, i dr.
  Izdano: (2020)
• Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
  od: Matter, Matthias S., i dr.
  Izdano: (2020)
• Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
  od: Tabbò, Fabrizio, i dr.
  Izdano: (2020)
• Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
  od: Russo, Alessandro, i dr.
  Izdano: (2020)
• Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
  od: Schoenmaekers, Janna Josephus Anna Oda, i dr.
  Izdano: (2020)